IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market.
What IOL files
- Others59
- Investor Meet36
- Updates24
- Important24
- Board Meeting9
- PPTs6
IOL Chemicals & Pharma's Board has approved the financial results for the quarter ended June 30, 2026. Consolidated Revenue from Operations soared to ₹756.26 Cr, with Net Profit reaching ₹64.40 Cr and EPS at ₹2.19.
IOLCP Board approved financial results for Q4 & FY26. It set the 39th AGM for Sept 2, 2026. Major operational boosts include a new 6000 MTPA Triacetin plant (₹16.88 Cr) & Pantoprazole capacity expansion (₹5.87 Cr), both funded by internal accruals. #IOLCP #BoardMeeting
IOL Chemicals & Pharma's board approved Q3 FY26 consolidated financial results. Revenue hit ₹580.39 Cr, Net Profit ₹20.58 Cr. An interim dividend of ₹1/share was declared (Record Date: Feb 17). The company also formed a new UK subsidiary, IOL Pharmaxis UK Limited.
IOL Chemicals' board approved the financial results for the quarter and half-year. Consolidated revenue for the quarter reached ₹567.53 Cr, with profit at ₹29.97 Cr, showcasing healthy growth.
IOL Chemicals and Pharmaceuticals' board has approved key strategic moves. Q1 FY26 consolidated financial results show Revenue from operations at Rs 551.69 Cr and Profit after Tax (PAT) at Rs 33.93 Cr. The company is setting up a Wholly Owned Subsidiary in the UK to boost its global business and...